Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BIS Research | PRODUCT CODE: 1114822

Cover Image

PUBLISHER: BIS Research | PRODUCT CODE: 1114822

Global Digital PCR Market - A Region and Country Analysis: Focus on Product, Application Type, End User, and Region - Analysis and Forecast, 2022-2032

PUBLISHED:
PAGES: 195 Pages
DELIVERY TIME: 1-5 business days
SELECT AN OPTION
PDF and Excel (1-3 User License)
USD 5250
PDF and Excel (Global License)
USD 8100

Add to Cart

“Global Digital PCR Market to Reach $2,847.8 Million by 2032.”

Global Digital PCR Market Industry Overview

The global digital PCR market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022-2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development.

Market Lifecycle Stage

The global digital PCR market is progressing rapidly with a significant increase in research and development (R&D) activities pertaining to a wide range of d-PCR products for disease detection, accentuating their criticality in healthcare. Digital PCR has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of disease diagnosis. Most players in the global digital PCR market offer products, such as kits and assays, systems, and reagents and consumables.

Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market. Several biotechnology and life sciences companies are working collaboratively on diagnostic test development and using d-PCR as a therapeutic means for applications in several disease indications to enable efficient diagnosis, treatment selection, and treatment monitoring.

Impact of COVID-19

The current global digital PCR market comprises kits and assays, system, and reagents and consumables. The unexpected crisis of the pandemic has surged the demand for essentials and increased the demand for digital PCR products. There was increased demand for digital PCR from biotechnology and life sciences companies. Overall, the impact of COVID-19 on the global d-PCR market size has been low-moderate. Some market players have reported a slight decline in sales. However, some new entrants in the global d-PCR market are expected to witness growth in the market. There is also a decline in revenues mostly due to the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thereby interrupting the supply chain. Several other products have been under development for years that may take longer than 2-4 years for commercialization. The pandemic has played a key role in enhancing the growth prospects of digital PCR-based diagnostics and is expected to indirectly aid in improving the market growth outlook.

Market Segmentation:

Segmentation 1: by Product

  • Kits and Assays
  • Systems
  • Reagents and Consumables

The global digital PCR market based on the product segment was dominated by kits and assays in 2021. This is due to an increasing number of research institutes involved in carrying out in vitro diagnostic (IVD) tests in the field of d-PCR-based diagnosis.

Segmentation 2: by Application

  • Oncology
  • Infectious Diseases
  • Rare Diseases
  • Gene Expression
  • Reproductive Genetics
  • Other Applications

In 2021, oncology dominated the application segment of the global digital PCR market.

Segmentation 3: by End User

  • Academic and Research Institutions
  • Biopharmaceutical Companies
  • Diagnostic Centers
  • Hospitals and Clinics

The academic and research institutions dominated the end-user segment in the global d-PCR market in 2021, as research laboratories, particularly, are most involved in carrying out research studies focused on identifying and understanding the diagnostic application of digital PCR.

Recent Developments in the Global Digital PCR Market

  • In March 2022, Stilla signed an agreement with 12 distributors throughout EMEA. This agreement grants distribution rights to Stilla's full product portfolio, including the six-color naica system.
  • In April 2022, Stilla and Promega Corporation signed a co-marketing agreement to offer a complete digital PCR workflow solution to provide their end users with optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assay, overall cancer research, and drug discovery.
  • In October 2021, Bio-Rad Laboratories, Inc. acquired Dropworks, Inc., a development stage company focused on developing a digital PCR product. The strategy was to increase and complement the company's life sciences product offerings.
  • In September 2021, Thermo Fisher Scientific launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results.

Demand - Drivers and Limitations

Following are the demand drivers for the global digital PCR market:

  • Technological Transformations Related to Digital PCR
  • Rising Adoption of Digital PCR among Various Applications
  • Increasing Activities in d-PCR Ecosystem

The market is expected to face some limitations too due to the following challenges:

  • Higher Cost of Droplet Digital PCR
  • Presence of Opaque Regulatory Framework

How can this report add value to an organization?

  • Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of healthcare have been affected, particularly PCR-based molecular diagnostics. The key components in the digital PCR market consist of a diverse range of d-PCR-based products, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report, along with pricing analysis considering the applications used in testing.
  • Competitive Strategy: Key players in the global d-PCR market analyzed and profiled profiled in the study, consisting of both products-based companies and a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global digital PCR market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Bio-Rad Laboratories, Inc.
  • Fluidigm Corporation
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Genetron Holdings Limited
  • JN Medsys
  • Stilla
  • Naveris, Inc.
  • SAGA Diagnostics
Product Code: BHP0944SB

Table of Contents

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
  • 1.2 Market Scope
    • 1.2.1 Scope of Work
    • 1.2.2 Key Questions Answered in the Report

2 Research Methodology

  • 2.1 Global Digital PCR Market: Research Methodology
  • 2.2 Data Sources
    • 2.2.1 Primary Data Sources
    • 2.2.2 Secondary Data Sources
  • 2.3 Market Estimation Model
  • 2.4 Criteria for Company Profiling

3 Market Overview

  • 3.1 Market Definition
  • 3.2 d-PCR vs. qPCR
  • 3.3 Market Footprint and Growth Potential
  • 3.4 COVID-19 Impact on the Global Digital PCR Market
    • 3.4.1 Impact on Research and Clinical Operations
    • 3.4.2 Impact on Market Players
    • 3.4.3 Impact on Market Growth

4 Industry Analysis

  • 4.1 Overview
    • 4.1.1 Regulatory Framework in the U.S.
    • 4.1.2 Regulatory Framework in European Union (EU)
    • 4.1.3 Regulatory Framework in Asia-Pacific
      • 4.1.3.1 Japan
      • 4.1.3.2 China
  • 4.2 Patent Analysis
    • 4.2.1 Patent Analysis (by Region)
    • 4.2.2 Patent Analysis (by Country)
    • 4.2.3 Patent Analysis (by Year)

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Impact Analysis
    • 5.2.1 Market Drivers
      • 5.2.1.1 Technological Transformations Related to Digital PCR
      • 5.2.1.2 Rising Adoption of Digital PCR among Various Applications
      • 5.2.1.3 Increasing Activities in d-PCR Ecosystem
    • 5.2.2 Market Restraints
      • 5.2.2.1 Higher Cost of Droplet Digital PCR
      • 5.2.2.2 Presence of Opaque Regulatory Framework
    • 5.2.3 Market Opportunities
      • 5.2.3.1 Extensive Adoption of Genetic Testing, especially in Developing Nations
      • 5.2.3.2 Increasing Adoption of d-PCR in Chronic Disease Diagnosis

6 Competitive Landscape

  • 6.1 Competitive Landscape
    • 6.1.1 Mergers and Acquisitions
    • 6.1.2 Synergistic Activities
    • 6.1.3 Product Launch and Approval Activities
    • 6.1.4 Expansion, Funding, and Other Activities
    • 6.1.5 Market-Share Analysis
    • 6.1.6 Growth-Share Analysis
      • 6.1.6.1 Growth-Share Analysis (by Company)
      • 6.1.6.2 Growth-Share Analysis (by Application Type)
  • 6.2 Supply Chain Analysis

7 Product

  • 7.1 Overview
    • 7.1.1 Systems
      • 7.1.1.1 Droplet Digital PCR Systems
      • 7.1.1.2 Chip-Based Digital PCR Systems
    • 7.1.2 Kits and Assays
      • 7.1.2.1 Droplet Digital PCR Systems
      • 7.1.2.2 Chip-Based Digital PCR
    • 7.1.3 Reagents and Consumables
      • 7.1.3.1 Droplet Digital PCR
      • 7.1.3.2 Chip-Based Digital PCR

8 Application Type

  • 8.1 Overview
    • 8.1.1 Oncology
      • 8.1.1.1 Solid Tumor
      • 8.1.1.2 Hematological Malignancies
    • 8.1.2 Infectious Diseases
      • 8.1.2.1 Respiratory Infections
      • 8.1.2.2 Gastrointestinal Infections
      • 8.1.2.3 Other Infectious Diseases
    • 8.1.3 Rare Diseases
      • 8.1.3.1 Inherited Trait Type
      • 8.1.3.2 Acquired Trait Type
    • 8.1.4 Reproductive Genetics
      • 8.1.4.1 Prenatal Diseases
      • 8.1.4.2 Postnatal Diseases
    • 8.1.5 Gene Expression
    • 8.1.6 Other Applications

9 End User

  • 9.1 Overview
    • 9.1.1 Academic and Research Institutions
    • 9.1.2 Hospitals and Clinics
    • 9.1.3 Diagnostic Centers
    • 9.1.4 Biopharmaceutical Companies

10 Region

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 U.K.
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 Australia
    • 10.4.4 South Korea
    • 10.4.5 Rest of Asia-Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest-of-Latin America
  • 10.6 Rest-of-the-World (RoW)
    • 10.6.1 Middle East
      • 10.6.1.1 K.S.A.
      • 10.6.1.2 Egypt
      • 10.6.1.3 Rest-of-Middle East
    • 10.6.2 Africa

11 Company Profiles

  • 11.1 Overview
  • 11.2 Bio-Rad Laboratories, Inc.
    • 11.2.1 Company Overview
    • 11.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Digital PCR Market
    • 11.2.3 Key Competitors of the Company
    • 11.2.4 Key Customers of the Company
    • 11.2.5 Synergistic Activities
    • 11.2.6 Business Strategies
      • 11.2.6.1 Product Launch/Approval
    • 11.2.7 Financials
    • 11.2.8 Analyst Perspective
  • 11.3 Fluidigm Corporation
    • 11.3.1 Company Overview
    • 11.3.2 Role of Fluidigm Corporation in the Global d- PCR Market
    • 11.3.3 Key Competitors of the Company
    • 11.3.4 Key Customers of the Company
    • 11.3.5 Corporate Strategies
      • 11.3.5.1 Synergistic Activities
    • 11.3.6 Financials
    • 11.3.7 Analyst Perspective
  • 11.4 F. Hoffmann-La Roche Ltd.
    • 11.4.1 Company Overview
    • 11.4.2 Role of F. Hoffmann-La Roche Ltd. in the Global d-PCR Market
    • 11.4.3 Key Competitors of the Company
    • 11.4.4 Corporate Strategies
      • 11.4.4.1 Synergistic Activities
    • 11.4.5 Financials
    • 11.4.6 Analyst Perspective
  • 11.5 Merck KGaA
    • 11.5.1 Company Overview
    • 11.5.2 Role of Merck KGaA in the Global Digital PCR Market
    • 11.5.3 Key Competitors of the Company
    • 11.5.4 Financials
    • 11.5.5 Analyst Perspective
  • 11.6 QIAGEN N.V.
    • 11.6.1 Company Overview
    • 11.6.2 Role of QIAGEN N.V. in the Global Digital PCR Market
    • 11.6.3 Key Competitors of the Company
    • 11.6.4 Corporate strategies
      • 11.6.4.1 Synergistic Activities
    • 11.6.5 Business Strategies
      • 11.6.5.1 Product Launch/Approval
    • 11.6.6 Financials
    • 11.6.7 Analyst Perspective
  • 11.7 Thermo Fisher Scientific Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Role of Thermo Fisher Scientific Inc. in the Global Digital PCR Market
    • 11.7.3 Key Competitors of the Company
    • 11.7.4 Corporate strategies
      • 11.7.4.1 Synergistic Activities
    • 11.7.5 Business Strategies
      • 11.7.5.1 Product Launch/Approval
    • 11.7.6 Financials
    • 11.7.7 Analyst Perspective
  • 11.8 Genetron Holdings Limited
    • 11.8.1 Company Overview
    • 11.8.2 Role of Genetron Holdings Limited in the Global Digital PCR Market
    • 11.8.3 Key Competitors of the Company
    • 11.8.4 Key Customers of the Company
    • 11.8.5 Corporate Strategies
      • 11.8.5.1 Synergistic Activities
    • 11.8.6 Financials
    • 11.8.7 Analyst Perspective
  • 11.9 JN Medsys
    • 11.9.1 Company Overview
    • 11.9.2 Role of JN Medsys in the Global Digital PCR Market
    • 11.9.3 Key Competitors of the Company
    • 11.9.4 Analyst Perspective
  • 11.1 Stilla
    • 11.10.1 Company Overview
    • 11.10.2 Role of Stilla in the Global Digital PCR Market
    • 11.10.3 Key Competitors of the Company
    • 11.10.4 Corporate Strategies
      • 11.10.4.1 Synergistic Activities
    • 11.10.5 Business Strategies
      • 11.10.5.1 Product Launch/Approval
    • 11.10.6 Analyst Perspective
  • 11.11 Naveris, Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Role of Naveris, Inc. in the Global Digital PCR Market
    • 11.11.3 Key Competitors of the Company
    • 11.11.4 Corporate strategies
      • 11.11.4.1 Synergistic Activities
    • 11.11.5 Analyst Perspective
  • 11.12 SAGA Diagnostics
    • 11.12.1 Company Overview
    • 11.12.2 Role of SAGA Diagnostics in the Global Digital PCR Market
    • 11.12.3 Key Competitors of the Company
    • 11.12.4 Corporate strategies
      • 11.12.4.1 Synergistic Activities
    • 11.12.5 Analyst Perspective
  • 11.13 Emerging Companies
    • 11.13.1 Precigenome LLC
    • 11.13.2 RevoSketch Inc.
Product Code: BHP0944SB

List of Figures

  • Figure 1: Global Digital PCR Market (by Product), $Million, 2021 and 2032
  • Figure 2: Global Digital PCR Market (by Application Type), $Million, 2021 and 2032
  • Figure 3: Global Digital PCR Market (by Region), $Million, 2021 and 2032
  • Figure 4: Global Digital PCR Market (by End User), $Million, 2021 and 2032
  • Figure 5: Global Digital PCR Market Segmentation
  • Figure 6: Global Digital PCR Market: Research Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Evolution of Digital PCR
  • Figure 11: Global Digital PCR Market, $Million, 2021-2032
  • Figure 12: Pre-COVID-19 and Post-COVID-19 Scenario of Global Digital PCR Market, $Million, 2019-2025
  • Figure 13: Components Considered for Clinical Actionability as per the IVDR
  • Figure 14: Region-Wise Analysis of Patents, January 2020-July 2022
  • Figure 15: Country-Wise Analysis of Patents, January 2020-July 2022
  • Figure 16: Year-Wise Analysis of Patents, January 2020-July 2022
  • Figure 17: Global Digital PCR Market Dynamics
  • Figure 18: Likert Scale
  • Figure 19: Impact Analysis of Market Drivers and Challenges on the Global Digital PCR Market
  • Figure 20: Share of Key Developments and Strategies, January 2019-January 2022
  • Figure 21: Share of Mergers and Acquisitions (by Company), January 2019-January 2022
  • Figure 22: Share of Synergistic Activities (by Company), January 2019-January 2022
  • Figure 23: Share of Product Launch and Approval Activities (by Company), January 2019-January 2022
  • Figure 24: Share of Expansion, Funding, and Other Activities (by Company), January 2019-January 2022
  • Figure 25: Market-Share Analysis for the Global Digital PCR Market, $Million, 2020 and 2021
  • Figure 26: Growth-Share Analysis of the Global Digital PCR Market (by Company), 2021
  • Figure 27: Growth-Share Analysis for Digital PCR Market (by Application Type), 2021
  • Figure 28: Supply Chain Analysis of the Global Digital PCR Market
  • Figure 29: Global Digital PCR Market (by Product)
  • Figure 30: Share of Global Digital PCR Market (by Product), $Million, 2021 and 2032
  • Figure 31: Digital PCR Systems Workflow
  • Figure 32: Global Digital PCR Market (Systems), $Million, 2021-2032
  • Figure 33: Sample Partitioning of Droplet Digital PCR System
  • Figure 34: Global Digital PCR Market (Droplet Digital PCR Systems), $Million, 2021-2032
  • Figure 35: Workflow of Chip-Based Digital PCR System
  • Figure 36: Global Digital PCR Market (Chip-Based Digital PCR Systems), $Million, 2021-2032
  • Figure 37: Global Digital PCR Market (Kits and Assays), $Million, 2021-2032
  • Figure 38: Global Digital PCR Market (Kits and Assays for Droplet Digital PCR Systems), $Million, 2021-2032
  • Figure 39: Global Digital PCR Market (Kits and Assays for Chip-Based Digital PCR Systems), $Million, 2021-2032
  • Figure 40: Global Digital PCR Market (Reagents and Consumables), $Million, 2021-2032
  • Figure 41: Global Digital PCR Market (Reagents and Consumables for Droplet Digital PCR Systems), $Million, 2021-2032
  • Figure 42: Global Digital PCR Market (Reagents and Consumables for Chip-Based Digital PCR), $Million, 2021-2032
  • Figure 43: Global Digital PCR Market (by Application Type)
  • Figure 44: Share of Global Digital PCR Market (by Application Type), $Million, 2021 and 2032
  • Figure 45: Estimated New Breast Cancer Cases among Female Population
  • Figure 46: Global Digital PCR Market (Oncology), $Million, 2021-2032
  • Figure 47: Global Digital PCR Market (Solid Tumor, by Oncology), $Million, 2021-2032
  • Figure 48: Global Digital PCR Market (Hematologic Malignancies, by Oncology), $Million, 2021-2032
  • Figure 49: Global Digital PCR Market (Infectious Diseases), $Million, 2021-2032
  • Figure 50: Distribution of Respiratory Infections
  • Figure 51: Global Digital PCR Market (Respiratory Infections, by Infectious Diseases), $Million, 2021-2032
  • Figure 52: Global Digital PCR Market (Gastrointestinal Infections, by Infectious Diseases), $Million, 2021-2032
  • Figure 53: Global Digital PCR Market (Other Infectious Diseases, by Infectious Diseases), $Million, 2021-2032
  • Figure 54: Global Burden of Rare Diseases
  • Figure 55: Global Digital PCR Market (Rare Diseases), $Million, 2021-2032
  • Figure 56: Global Digital PCR Market (Inherited Trait Type, by Rare Diseases), $Million, 2021-2032
  • Figure 57: Global Digital PCR Market (Acquired Trait Type, by Rare Diseases), $Million, 2021-2032
  • Figure 58: Global Digital PCR Market (Reproductive Genetics), $Million, 2021-2032
  • Figure 59: Global Digital PCR Market (Prenatal Diseases, by Reproductive Genetics), $Million, 2021-2032
  • Figure 60: Global Digital PCR Market (Postnatal Diseases, by Reproductive Genetics), $Million, 2021-2032
  • Figure 61: Global Digital PCR Market (Gene Expression), $Million, 2021-2032
  • Figure 62: Global Digital PCR Market (Other Applications), $Million, 2021-2032
  • Figure 63: Global Digital PCR Market (by End User)
  • Figure 64: Share of Global Digital PCR Market (by End User), $Million, 2021 and 2032
  • Figure 65: Global Digital PCR Market (Academic and Research Institutions), $Million, 2021-2032
  • Figure 66: Global Digital PCR Market (Hospitals and Clinics), $Million, 2021-2032
  • Figure 67: Global Digital PCR Market (Diagnostic Centers), $Million, 2021-2032
  • Figure 68: Global Digital PCR Market (Biopharmaceutical Companies), $Million, 2021-2032
  • Figure 69: Global Digital PCR Market Snapshot (by Region)
  • Figure 70: Global Digital PCR Market (by Region), $Million, 2021-2032
  • Figure 71: Share of Global Digital PCR Market (by Region), $Million, 2021 and 2032
  • Figure 72: North America Digital PCR Market, $Million, 2021-2032
  • Figure 73: Growth Potential Analysis (by Country), $Million, 2021-2032
  • Figure 74: U.S. Digital PCR Market, $Million, 2021-2032
  • Figure 75: U.S. Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 76: Canada Digital PCR Market, $Million, 2021-2032
  • Figure 77: Canada Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 78: Europe Digital PCR Market, $Million, 2021-2032
  • Figure 79: Growth Potential Analysis (by Country), $Million, 2021-2032
  • Figure 80: Germany Digital PCR Market, $Million, 2021-2032
  • Figure 81: Germany Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 82: France Digital PCR Market, $Million, 2021-2032
  • Figure 83: France Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 84: U.K. Digital PCR Market, $Million, 2021-2032
  • Figure 85: U.K. Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 86: Italy Digital PCR Market, $Million, 2021-2032
  • Figure 87: Italy Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 88: Spain Digital PCR Market, $Million, 2021-2032
  • Figure 89: Spain Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 90: Rest-of-Europe Digital PCR Market, $Million, 2021-2032
  • Figure 91: Rest-of-Europe Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 92: Asia-Pacific Digital PCR Market, $Million, 2021-2032
  • Figure 93: Growth Potential Analysis (by Country), $Million, 2021-2032
  • Figure 94: Japan Digital PCR Market, $Million, 2021-2032
  • Figure 95: Japan Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 96: China Digital PCR Market, $Million, 2021-2032
  • Figure 97: China Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 98: Australia Digital PCR Market, $Million, 2021-2032
  • Figure 99: Australia Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 100: South Korea Digital PCR Market, $Million, 2021-2032
  • Figure 101: South Korea Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 102: Rest-of-Asia-Pacific Digital PCR Market, $Million, 2021-2032
  • Figure 103: Rest-of-Asia-Pacific Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 104: Latin America Digital PCR Market, $Million, 2021-2032
  • Figure 105: Growth Potential Analysis (by Country), $Million, 2021-2032
  • Figure 106: Brazil Digital PCR Market, $Million, 2021-2032
  • Figure 107: Brazil Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 108: Mexico Digital PCR Market, $Million, 2021-2032
  • Figure 109: Mexico Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 110: Rest-of-Latin America Digital PCR Market, $Million, 2021-2032
  • Figure 111: Rest-of-Latin America Digital PCR Market (by End User), $Million, 2021-2032
  • Figure 112: Rest-of-the-World Digital PCR Market, $Million, 2021-2032
  • Figure 113: Middle East Digital PCR Market, $Million, 2021-2032
  • Figure 114: K.S.A. Digital PCR Market, $Million, 2021-2032
  • Figure 115: Turkey Digital PCR Market, $Million, 2021-2032
  • Figure 116: Egypt Digital PCR Market, $Million, 2021-2032
  • Figure 117: Rest-of-Middle East Digital PCR Market, $Million, 2021-2032
  • Figure 118: Africa Digital PCR Market, $Million, 2021-2032
  • Figure 119: Total Number of Companies Profiled
  • Figure 120: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 121: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 122: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 123: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 124: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 125: Fluidigm Corporation: Product Portfolio
  • Figure 126: Fluidigm Corporation: Overall Financials, $Million, 2019-2021
  • Figure 127: Fluidigm Corporation: Revenue (by Region), $Million, 2019-2021
  • Figure 128: Fluidigm Corporation: R&D Expenditure, $Million, 2019-2021
  • Figure 129: F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Figure 130: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 131: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2019-2021
  • Figure 132: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2019-2021
  • Figure 133: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2019-2021
  • Figure 134: Merck KGaA: Product Portfolio
  • Figure 135: Merck KGaA: Overall Financials, $Million, 2019-2021
  • Figure 136: Merck KGaA: Revenue (by Segment), $Million, 2019-2021
  • Figure 137: Merck KGaA: Revenue (by Region), $Million, 2019-2021
  • Figure 138: Merck KGaA: R&D Expenditure, $Million, 2019-2021
  • Figure 139: QIAGEN N.V.: Product Profile
  • Figure 140: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
  • Figure 141: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
  • Figure 142: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
  • Figure 143: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
  • Figure 144: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 145: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
  • Figure 146: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 147: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 148: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 149: Genetron Holdings Limited: Product Portfolio
  • Figure 150: Genetron Holdings Limited: Overall Financials, $Million, 2019-2021
  • Figure 151: Genetron Holdings Limited: Revenue (by Segment), $Million, 2019-2021
  • Figure 152: Genetron Holdings Limited: R&D Expenditure, $Million, 2019-2021
  • Figure 153: JN Medsys: Product Portfolio
  • Figure 154: Stilla: Product Portfolio
  • Figure 155: Naveris, Inc.: Product Portfolio
  • Figure 156: SAGA Diagnostics: Product Portfolio

List of Tables

  • Table 1: Non-Invasive Prenatal Testing Performance by Digital PCR
  • Table 2: Advantages of Digital PCR over Conventional PCR
  • Table 3: Digital PCR Diagnostics Solutions Offered for COVID-19
  • Table 4: Registration Criteria for IVD Medical Devices as per the CFDA
  • Table 5: Different Technology-Based Products
  • Table 6: Different Application-Based Products
  • Table 7: Companies Providing Digital PCR Systems
  • Table 8: Companies Providing Droplet Digital PCR Systems
  • Table 9: Companies Providing Chip-Based Digital PCR Systems
  • Table 10: Companies Providing Kits and Assays for Digital PCR Systems
  • Table 11: Companies Providing Reagents and Consumables for Digital PCR Systems
  • Table 12: Hematologic Malignancies and Their Targets Using Droplet Digital PCR Systems
  • Table 13: North America: Market Dynamics
  • Table 14: Europe: Market Dynamics
  • Table 15: Asia-Pacific: Market Dynamics
  • Table 16: Latin America: Market Dynamics
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!